Application of pharmaceutical composition of rapamycin type drugs and omega-3 fatty acid to preparation of drugs for treating kidney cancer

Abstract

The invention discloses application of a pharmaceutical composition of rapamycin type drugs and omega-3 fatty acid to preparation of drugs for treating kidney cancer. The application of the pharmaceutical composition disclosed by the invention has the beneficial effects that the rapamycin type drugs and the omega-3 fatty acid are combined and added into a mouse with kidney cancer cells and transplanted tumor and cultured in vitro, the effects of the rapamycin type drugs and the omega-3 fatty acid for inhibiting the growth of the kidney cancer cells, promoting apoptosis of the kidney cancer cells and inhibiting the tumor growth of the mouse with the transplanted tumor and the like are obviously improved; the rapamycin type drugs and the omega-3 fatty acid have obvious synergistic effect when being used for treating the kidney cancer, so that the effect for treating the kidney cancer is improved, simultaneously the toxic and side effects such as metabolic disorders and blood-lipid increase caused by the rapamycin type drugs can be reduced, and the pharmaceutical composition has an important clinical drug application prospect.

Description

technical field [0001] The invention belongs to the field of medical biotechnology, and in particular relates to the application of the combination of rapamycin and omega-3 fatty acid in the preparation of medicine for treating kidney cancer. Background technique [0002] Renal cell carcinoma (RCC) is the most common malignant disease of the kidney, and it is one of the three major malignant tumors of the urinary system together with prostate cancer and bladder cancer. As the main malignant tumor of the kidney, renal cell carcinoma accounts for about 2-3% of the overall incidence of cancer, and ranks sixth and seventh among malignant tumors in men and women. In the past 30 years, the morbidity and mortality of renal cell carcinoma in the world have been increasing year by year, with about 200,000 newly diagnosed cases and about 100,000 deaths from the disease every year. 25% of patients have developed distant metastasis at the time of diagnosis, and about 30% of patients ha...

AI Technical Summary

Problems solved by technology

[0006] Therefore, the technical problem to be solved by the present invention is to overcome the fact that the pharmaceutical composition for assisting rapamycin in the treatment of kidney cancer in the prior art cannot increase the anti-kidney cancer activity of rapamycin while reducing the toxic and side effects of rapamycin, Improve the defect of metabolic disorder caused by rapamycin, and then provide the use of the pharmaceutical composition of rapamycin and omega-3 fatty acid in the preparation of medicine for treating kidney cancer

Images